FDA Approves Drug For Advanced Pancreatic Cancer; Drug Nearly Doubles Survival In Trial

The US FDA has approved Rasonque, a once-daily targeted drug for metastatic pancreatic cancer. A Phase 3 trial revealed that the medication nearly doubles patient survival rates. Now available across the U.S., the drug is priced at $39,800 for a 30-day supply. This approval provides a new treatment option for advanced pancreatic cancer patients, following clinical evidence of its effectiveness in improving survival outcomes compared to existing therapies for this specific metastatic condition.